DFX Intelligence
Borrowers
196 borrower groups currently held, grade A and BWhat a borrower group isA borrower group is every spelling of one credit agreement's borrower across the BDCs that hold it (Icefall Parent, Icefall Topco and Icefall Bidco are one). Grade A and B groups are listed; a short one-word stem (grade C) is kept apart and never merged across filers. Principal is the sum of BDC pieces and is a lower bound.Principal and marks are the filers' figures at each BDC's latest quarter end, summed. Maturity is the filer's tagged date or the date written into the identifier; a BDC that tags neither leaves it unstated.
Industry as filed contains “Pharmaceuticals” (remove)
Start from
196 borrower groups
| Borrower | Sponsor | BDCs | Principal held | On cost | Spread | Next maturity | First seen |
|---|---|---|---|---|---|---|---|
| AArete Investment, LLC Life sciences | unattributed | 2 | at least $9.9M | 102c | 0 pts | Jun 5, 2031 | Jun 30, 2025 |
| PAI Pharma Pai Middle Tier, LLC Life sciences | unattributed | 2 | at least $9.8M | 98c | n/a | Feb 13, 2032 | Mar 31, 2025 |
| Psychiatric Medical Care LLC Life sciences | unattributed | 2 | at least $9.5M | 100c | n/a | Jul 1, 2032 | Sep 30, 2025 |
| S•••••• A• L• Life sciences · grade B | unattributed | 2 | at least $9.4M | 115c | n/a | Feb 29, 2032 | Mar 31, 2025 |
| A••••••• C••• A••••••• H••••• L•• Life sciences | unattributed | 2 | at least $9.1M | 101c | n/a | Aug 20, 2030 | Sep 30, 2025 |
| R•• N•••••• Life sciences | unattributed | 2 | at least $9.0M | 100c | n/a | Oct 17, 2031 | Dec 31, 2024 |
| P••••••• L•• Life sciences | unattributed | 4 | at least $8.9M | 95c | n/a | Jul 6, 2028 | Dec 31, 2021 |
| S•• B••••• L•• Life sciences | unattributed | 3 | at least $8.9M | 63c | 57 pts | Jan 20, 2027 | Dec 31, 2022 |
| A•• I••••••• Life sciences | R••••••••• C•••••• P••••••• inferred | 2 | at least $8.6M | 101c | n/a | Mar 19, 2032 | Mar 31, 2025 |
| N••••• L••••••••• I•• Life sciences | unattributed | 1 | at least $8.5M | 104c | n/a | Apr 14, 2027 | Jun 30, 2026 |
| M•••• • A••••••• Life sciences | unattributed | 2 | at least $8.0M | 101c | n/a | May 3, 2029 | Jun 30, 2023 |
| E•••• M•••• B•• Life sciences · grade B | unattributed | 1 | at least $7.7M | 62c | n/a | Jul 31, 2029 | Dec 31, 2022 |
| O•••••• Life sciences | unattributed | 5 | at least $7.6M | 101c | n/a | Nov 21, 2030 | Dec 31, 2021 |
| R••••• O••••••••• Life sciences | unattributed | 2 | at least $7.5M | 101c | n/a | Feb 28, 2031 | Mar 31, 2025 |
| E••••••• P••••••• Life sciences | Sponsor not establishedpossible: M••••••• C•••••• L•• (a company of this name is on the sponsor's portfolio page) | 2 | at least $6.6M | 101c | n/a | Oct 5, 2029 | Dec 31, 2023 |
| A••••••••• Life sciences | unattributed | 4 | at least $6.4M | 94c | n/a | Jun 20, 2028 | Dec 31, 2021 |
| A•••••••• T••••••••• I•• Life sciences | unattributed | 1 | at least $6.3M | 100c | n/a | May 12, 2031 | Sep 30, 2025 |
| N•••••••• L•• Life sciences | unattributed | 1 | at least $6.1M | 95c | n/a | May 15, 2027 | Jun 30, 2026 |
| O•••• Life sciences · grade B | unattributed | 1 | at least $5.8M | 101c | n/a | Jun 30, 2028 | Jun 30, 2025 |
| E••• S••••••• G•••• Life sciences | unattributed | 3 | at least $5.8M | 98c | n/a | Jun 28, 2029 | Dec 31, 2022 |
| A•••••• H•••••• G••• Life sciences | unattributed | 2 | at least $5.8M | 99c | n/a | Nov 29, 2032 | Dec 31, 2025 |
| G•••••• B••••••••• I•• Life sciences | unattributed | 1 | at least $5.6M | 105c | n/a | Sep 13, 2027 | Jun 30, 2026 |
| D••••• I•• Life sciences | unattributed | 3 | at least $5.5M | 100c | n/a | May 9, 2031 | Jun 30, 2024 |
| R••••••••• Life sciences | unattributed | 5 | at least $5.5M | 102c | n/a | Dec 19, 2030 | Dec 31, 2022 |
| S••••• B••••••••• H••••••••• L•• Life sciences | unattributed | 6 | at least $5.0M | 74c | n/a | Dec 31, 2029 | Sep 30, 2021 |
| G••••• A•• Life sciences | unattributed | 3 | at least $5.0M | 100c | 0 pts | Dec 13, 2032 | Dec 31, 2025 |
| V•••• B••••• I•• Life sciences | unattributed | 2 | at least $4.9M | 100c | n/a | Dec 15, 2031 | Dec 31, 2024 |
| S•••••• L•• Life sciences · grade B | unattributed | 1 | at least $4.8M | 100c | n/a | Dec 29, 2026 | Sep 30, 2023 |
| M••••• 5••• G••• Life sciences | unattributed | 2 | at least $4.6M | 101c | n/a | May 28, 2028 | Dec 31, 2021 |
| R•••••••• Life sciences | Sponsor not establishedpossible: W••••••• H••••• I••••••••• L•• (a company of this name is on the sponsor's portfolio page) | 1 | at least $4.5M | 74c | n/a | Jul 21, 2028 | Dec 31, 2022 |
| Q••••••••• C••••••••• Life sciences | unattributed | 5 | at least $4.0M | 99c | n/a | Aug 20, 2032 | Sep 30, 2025 |
| M•••• • A••••••• Life sciences | unattributed | 1 | at least $4.0M | 102c | n/a | May 3, 2029 | Jun 30, 2023 |
| P••••••• O••• H••••• Life sciences | Sponsor not establishedpossible: I••••••• C•••••• P•••••••• L•• (a company of this name is on the sponsor's portfolio page) | 1 | at least $4.0M | 101c | n/a | Nov 16, 2028 | Dec 31, 2023 |
| i•••• P••••••••• P•• L•••••• Life sciences | Sponsor not establishedpossible: P•••••• E••••• P••••••• P•• L•••••• (a company of this name is on the sponsor's portfolio page) | 1 | at least $3.9M | 100c | n/a | Nov 1, 2031 | Dec 31, 2022 |
| P••••••• P••••••• Life sciences | unattributed | 3 | at least $3.8M | 100c | n/a | Feb 28, 2029 | Mar 31, 2024 |
| E••••• A••••• H•••••• I•• Life sciences | unattributed | 3 | at least $3.8M | 100c | n/a | Oct 31, 2032 | Jun 30, 2024 |
| S••••• S•••• Life sciences | unattributed | 2 | at least $3.6M | 102c | n/a | Mar 25, 2031 | Dec 31, 2024 |
| A•• T••• H•••••••• I•• Life sciences | unattributed | 6 | at least $3.5M | 100c | n/a | Dec 15, 2032 | Sep 30, 2024 |
| N•••••• Life sciences | unattributed | 2 | at least $3.4M | 106c | n/a | Aug 29, 2031 | Sep 30, 2024 |
| Q•• A•••• 4• P•• L•• Life sciences | unattributed | 2 | at least $3.2M | 99c | n/a | Feb 5, 2032 | Mar 31, 2026 |
| A•••• P•••• Life sciences | unattributed | 1 | at least $3.1M | 100c | n/a | Oct 31, 2033 | Jun 30, 2025 |
| U••• F••• a•• A•••• S••••••••• Life sciences | unattributed | 1 | at least $3.0M | 99c | n/a | Sep 15, 2026 | Dec 31, 2023 |
| n•••••• Life sciences · grade B | unattributed | 1 | at least $2.6M | 32c | n/a | Dec 15, 2028 | Dec 31, 2022 |
| A•••••••• E•••••• Life sciences | unattributed | 1 | at least $2.4M | 66c | n/a | Jun 13, 2029 | Dec 31, 2022 |
| F•••••••• Life sciences | unattributed | 2 | at least $2.4M | 99c | n/a | Mar 30, 2029 | Sep 30, 2022 |
| W•••••• D••••• Life sciences | Sponsor not establishedpossible: C•••• S••••• C•••••• (a company of this name is on the sponsor's portfolio page) | 3 | at least $2.2M | 99c | n/a | Jan 30, 2032 | Dec 31, 2022 |
| G••••••• A••••••••• C•••• T••• B• L••• Life sciences | unattributed | 1 | at least $2.2M | 99c | n/a | Oct 1, 2027 | Dec 31, 2022 |
| W•••••• Life sciences | unattributed | 3 | at least $2.0M | 100c | n/a | Mar 10, 2028 | Dec 31, 2022 |
| S•••••• Life sciences | unattributed | 4 | at least $1.9M | 75c | n/a | Jul 18, 2031 | Dec 31, 2022 |
| U••••••• R••••••••• Life sciences | Sponsor not establishedpossible: R••••••••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 1 | at least $1.9M | 94c | n/a | Nov 20, 2029 | Dec 31, 2022 |
The borrower, lender and sponsor names past the first 3 rows are hidden. Open a row to reveal that record with a free account (5 a month), or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source is public either way.